Mandate

Vinge advises Carnegie and Nordea in connection with the listing of Volati on Nasdaq Stockholm

November 17, 2016

Vinge advises Carnegie Investment Bank AB (publ) and Nordea Bank AB (publ) who are acting as Joint Global Coordinators and Joint Bookrunners in connection with the listing of the common shares and preference shares in Volati AB (publ) on Nasdaq Stockholm. The company has applied for the company’s shares to be admitted for trading and Nasdaq Stockholm has approved the company’s shares for listing subject to customary conditions. A prospectus is expected to be published on or around 18 November 2016 and first day of trading is expected to be on or around 30 November 2016.

Volati is an industrial group comprising 13 business units organised into three business areas: Trading, Industry and Consumer. Volati has some 40 operating companies in 15 countries, with Sweden accounting for the largest share of net sales. Acquisitions are central in Volati’s strategy and Volati primarily acquires companies with proven business models, leading market positions and strong cash flows at reasonable valuations, and develops these with an emphasis on long-term creation.   

Vinge’s team consists of Dain Hård Nevonen, Erik Sjöman and Sofie Bjärtun.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025